U.S., Aug. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07770802) titled 'Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer' on Aug. 13.
Brief Summary: A Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting Preconditioning with Fludarabine and Cyclophosphamide and Subsequent Interleukin-2 Therapy in Patients with Advanced Renal Cancer.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Clear Cell Renal Cell Carcinoma
Intervention:
DRUG: Cyclophosphamid
Cyclophosphamide administered via intravenous infusion once daily for 3 consecutive days.
DRU...